Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

被引：0
|
作者：
Joseph Gathe
Jose R. Arribas
Jan Van Lunzen
Will Garner
Rebecca M. Speck
Randall Bender
Sanatan Shreay
Thai Nguyen
机构：
[1] Therapeutic Concepts,
[2] PA,undefined
[3] Hospital La Paz,undefined
[4] IdiPaz,undefined
[5] Universitaetsklinikum Hamburg-Eppendorf,undefined
[6] Gilead Sciences,undefined
[7] Inc.,undefined
[8] Evidera,undefined
来源：
The Patient - Patient-Centered Outcomes Research | 2015年 / 8卷
关键词：
Physical Component Summary; Mental Component Summary; Tenofovir Disoproxil Fumarate; Mental Component Summary Score; Emtricitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：445 / 454
页数：9
相关论文
共 33 条
  • [21] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged>65 or older: week 48 results from a phase 3b, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J-M
    Pulido, F.
    De Wit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    McNicholl, I.
    Haubrich, R.
    Gallant, J.
    HIV MEDICINE, 2019, 20 : 138 - 138
  • [22] Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial
    Brunetta, Jason
    Moreno Guillen, Santiago
    Antinori, Andrea
    Yeni, Patrick
    Wade, Barbara
    Johnson, Margaret
    Shalit, Peter
    Ebrahimi, Ramin
    Johnson, Bethsheba
    Walker, Ivan
    De-Oertel, Shampa
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2015, 8 (03): : 257 - 267
  • [23] Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial
    Jason Brunetta
    Santiago Moreno Guillén
    Andrea Antinori
    Patrick Yeni
    Barbara Wade
    Margaret Johnson
    Peter Shalit
    Ramin Ebrahimi
    Bethsheba Johnson
    Ivan Walker
    Shampa De-Oertel
    The Patient - Patient-Centered Outcomes Research, 2015, 8 : 257 - 267
  • [24] Switch to fi xed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial
    Zhang, Fujie
    Wu, Hao
    Cai, Weiping
    Ma, Ping
    Zhao, Qingxia
    Wei, Hongxia
    Lu, Hongzhou
    Wang, Hui
    He, Shenghua
    Chen, Zhu
    Chen, Yaokai
    Wang, Min
    Wan, Wan
    Fu, Heliang
    Qin, Hong
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 49
  • [25] Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Raffi, Francois
    Pulido, Federico
    Gracia Mateo-Garcia, Maria
    Molina, Jean-Michel
    Ong, Edmund
    Shao, Yongwu
    Piontkowsky, David
    Das, Moupali
    McNicholl, Ian
    Haubrich, Richard
    LANCET HIV, 2019, 6 (10): : E655 - E666
  • [26] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study (vol 4, pg e546, 2017)
    Orrell, C.
    Hagins, D. P.
    Belonosova, E.
    LANCET HIV, 2017, 4 (12): : E535 - E535
  • [27] Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
    Ramgopal, Moti N.
    Castagna, Antonella
    Cazanave, Charles
    Diaz-Brito, Vicens
    Dretler, Robin
    Oka, Shinichi
    Osiyemi, Olayemi
    Walmsley, Sharon
    Sims, James
    Di Perri, Giovanni
    Sutton, Kenneth
    Sutherland-Phillips, Denise
    Berni, Alessandro
    Latham, Christine L.
    Zhang, Feifan
    D'Amico, Ronald
    Bernaldez, Miguel Pascual
    Van Solingen-Ristea, Rodica
    Van Eygen, Veerle
    Patel, Parul
    Chounta, Vasiliki
    Spreen, William R.
    Garges, Harmony P.
    Smith, Kimberly
    van Wyk, Jean
    LANCET HIV, 2023, 10 (09): : E566 - E577
  • [28] Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
    Aboud, Michael
    Kaplan, Richard
    Lombaard, Johannes
    Zhang, Fujie
    Hidalgo, Jose A.
    Mamedova, Elmira
    Losso, Marcelo H.
    Chetchotisakd, Ploenchan
    Brites, Carlos
    Sievers, Jorg
    Brown, Dannae
    Hopking, Judy
    Underwood, Mark
    Nascimento, Maria Claudia
    Punekar, Yogesh
    Gartland, Martin
    Smith, Kimberly
    LANCET INFECTIOUS DISEASES, 2019, 19 (03): : 253 - 264
  • [29] Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults
    Orkin, C.
    Molina, J-M
    Gallant, J.
    Negredo, E.
    Gathe, J.
    Eron, J.
    van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Petrovic, R.
    Opsomer, M.
    HIV MEDICINE, 2018, 19 : S32 - S32
  • [30] Switching to bictegravir/ emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance - A phase IV randomized, open-label pilot study (PIBIK study)
    Iwuji, C.
    Waters, L.
    Milinkovic, A.
    Orkin, C.
    Fox, J.
    Post, F.
    Perry, N.
    Bruce, C.
    Dailey, N.
    To, Y.
    Bremner, S.
    Geretti, A. M.
    Churchill, D.
    HIV MEDICINE, 2023, 24 : 681 - 683
1234